Oraya Supplement: Oraya Therapy for Wet AMD, Real World Clinical Outcomes

Age-related macular degeneration (AMD) affects an estimated 30 million to 50 million people worldwide and is the leading cause of severe vision loss in higher income countries. Neovascular AMD accounts for about 10 per cent of AMD cases, but for about 90 per cent of the severe vision loss that AMD causes. It affects approximately 1.3 per cent of people over 50 years old, with approximately 600,000 new cases of neovascular AMD diagnosed annua
Download Supplement - click here
Tags: ocular pathology
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.